Catalent (NYSE:CTLT) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a note issued to investors on Thursday.
According to Zacks, “Catalent, Inc. provides advanced delivery technologies and development solutions for drugs, biologics and consumer health products. It operates through Oral Technologies, Medication Delivery Solutions, and Development & Clinical Services. The Oral Technologies segment address the full diversity of the pharmaceutical industry including small molecules, large molecule biologics and consumer health products. The Medication Delivery Solutions segment offers formulation, development, and manufacturing services for delivery of drugs and biologics administered through injection, inhalation, and ophthalmic routes. The Development and Clinical Services segment provides manufacturing, packaging, storage, and inventory management services for drugs and biologics in clinical trials. Catalent, Inc. is headquartered in Somerset, New Jersey. “
Other equities research analysts also recently issued reports about the company. Bank of America reaffirmed a “buy” rating and issued a $45.00 price target (up from $40.00) on shares of Catalent in a research report on Wednesday, September 20th. BidaskClub raised Catalent from a “hold” rating to a “buy” rating in a research report on Thursday, October 5th. First Analysis initiated coverage on Catalent in a research report on Friday, January 5th. They issued an “equal weight” rating on the stock. Needham & Company LLC reaffirmed a “hold” rating on shares of Catalent in a research report on Monday, October 23rd. Finally, ValuEngine downgraded Catalent from a “buy” rating to a “hold” rating in a research report on Friday, December 1st. Six investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Catalent has a consensus rating of “Buy” and a consensus target price of $44.44.
Catalent (NYSE:CTLT) last issued its quarterly earnings results on Monday, November 6th. The company reported $0.21 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.20 by $0.01. The company had revenue of $543.90 million for the quarter, compared to the consensus estimate of $490.75 million. Catalent had a return on equity of 23.97% and a net margin of 5.01%. The firm’s revenue was up 23.0% compared to the same quarter last year. During the same period last year, the business posted $0.16 earnings per share. analysts forecast that Catalent will post 1.47 earnings per share for the current fiscal year.
In other news, Director Uwe Roehrhoff bought 7,500 shares of the firm’s stock in a transaction that occurred on Tuesday, November 21st. The shares were acquired at an average cost of $39.22 per share, with a total value of $294,150.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider John R. Chiminski sold 181,458 shares of Catalent stock in a transaction dated Tuesday, December 12th. The stock was sold at an average price of $39.62, for a total value of $7,189,365.96. The disclosure for this sale can be found here. 1.70% of the stock is owned by company insiders.
A number of hedge funds have recently added to or reduced their stakes in the stock. Advisor Group Inc. grew its position in Catalent by 1.3% during the second quarter. Advisor Group Inc. now owns 5,185 shares of the company’s stock worth $180,000 after buying an additional 65 shares in the last quarter. Stifel Financial Corp grew its position in Catalent by 0.9% during the second quarter. Stifel Financial Corp now owns 10,694 shares of the company’s stock worth $377,000 after buying an additional 96 shares in the last quarter. People s United Financial Inc. boosted its holdings in Catalent by 1.9% during the second quarter. People s United Financial Inc. now owns 18,952 shares of the company’s stock valued at $665,000 after purchasing an additional 356 shares in the last quarter. Acrospire Investment Management LLC boosted its holdings in Catalent by 72.2% during the second quarter. Acrospire Investment Management LLC now owns 3,100 shares of the company’s stock valued at $109,000 after purchasing an additional 1,300 shares in the last quarter. Finally, First Bank & Trust boosted its holdings in Catalent by 54.2% during the fourth quarter. First Bank & Trust now owns 3,764 shares of the company’s stock valued at $155,000 after purchasing an additional 1,323 shares in the last quarter. 99.37% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: This piece of content was published by Ticker Report and is the sole property of of Ticker Report. If you are accessing this piece of content on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright laws. The original version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/3144821/zacks-investment-research-downgrades-catalent-ctlt-to-hold.html.
Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.